6
transduced cells were placed in femoral defects of syngeneic rats. Procedures were completed in the same day including the transduction time of 2 hours. In the "cultured bone marrow" strategy, the cells (C-RBMCs) were harvested, expanded in tissue culture and were transduced overnight with the LV-TSTA-GFP. 5x10 6 transduced cells were implanted in the rat defects. Animals were sacrificed at 4, 14, 28 and 56 days after surgery (n=5 per group). DNA from defect site and internal organs was extracted for quantitation of viral copies using RT-qPCR with detectability at >50 copies/μg. 56 day tissue samples were used for histological analysis as well. To assess the biosafety of this applied gene therapy strategy, a large scale integration site analysis using linear amplification mediated PCR (LAM-PCR) and non-restrictive (nr) LAM-PCR in combination with subsequent 454 pyrosequencing was conducted as previously described [3, 4] . Genomic DNA of cells harvested at two distinct time points after cell implantation (4 days, 56 days) of 5 animals of the C-RBMC and SD-RBMC groups, respectively, was used to determine lentiviral vector integration sites (IS). Results: In SD-RBMC animals viral copies were detectable in the defect site at 4 days (1.95x10 8 -7.24x10 8 copies/μg). The copy numbers gradually declined to <50-8451 copies/μg at 8w (Figure 1 ). Viral copies were minimally detected in blood, testis, brain and the GI. Heart and spleen were positive only in one animal and copies were undetectable in the lung, kidney and BM at all time points. No consistent pattern of organ involvement was noticed. In the C-RBMC animals, 6.41x10 4 -6.75x10 5 copies/μg were detected in the defect site at 4 days. There was a decline in the viral copies at 2w (<50-3142 copies/μg) and 4w (998-6731 copies/μg), but at 8w there was a relative rise (about 100 fold) in the number of the viral vectors in the defect site of 4 animals compared to the previous time points (18360-2.58x10 5 copies/μg) ( Figure 2 ). The pattern of tissue distribution was non-specific and levels were detectable in blood more commonly than other organs. No viral copies were detected in BM, testis, heart and lung. No histological abnormalities were noted in either group. Large scale integration site analysis revealed 630 unique exactly mappable lentiviral vector IS. The majority of IS (590 IS) was identified in C-RBMC group (579 IS at 4 days; 14 IS at 56 days). In contrast, an in depth LAM-PCR analysis performed on samples of the SD-RBMC group identified merely 40 unique mappable IS (13 IS at 4 days; 27 IS at 56 days). The landscape of lentiviral vector integration revealed a statistical significant increased frequency of integration events occurring within gene coding regions (36.03%; combined data set C-RBMC and SD.RBMC group). The integration within genes occurred over the entire gene coding region, no enrichment around transcriptional start site was observed. Only two of the vector targeted genes (Zdhhc13, Mfap5) in this study are reported in the Retrovirus and Transposon tagged Cancer Gene Database (RTCGD). For both genes, only one single integration event is described in RTCGD. None of the identified CIS genes has been listed in the Cancer Gene Census Database (CGC). Discussion: We demonstrated that the LV-TSTA transduced cells remain in the defect site for at least 8 weeks. The number of viral copies in SD-RBMC group decreased over time which implies a reduction in the number of transduced cells. The observed late increase in the defect viral copies in the C-RBMC group may be due to clonal expansion or activation of growth factors and need further investigations including insertion site analysis studies. The involvement of internal organs was random and different from previous reports 1 which had shown the liver, spleen and bone marrow as common sites of virus detection. This may be due to the differences in the gene therapy methods used in other studies (in vivo vs. ex vivo), factors related to the host or site of implantation. Analyses of 'common integration sites' (CIS) has been shown to be a potential indicator for clonal skewing. CIS analyses on the combined IS data set (630 IS) showed a low frequency of CIS detection (8 CIS of 2nd order) and the absence of genes previously been linked to adverse events in clinical gene therapy studies. In summary our study demonstrated that viral copies are detectable in the defects which decreased over time. There were no consistent findings of viral copies in internal organs which is encouraging to develop this strategy for use in humans. Although no clear explanation was found with regards to the increased viral copy numbers observed in 4 out of 5 of the C-RBMC animals at 8 weeks, analysis of the IS sites indicated a relatively safe gene transfer coupled with low integration frequencies. Significance: These findings are encouraging with regard to safety of the gene therapy approach, but large animal studies need to be done to confirm the safety of the gene therapy.
